The vaccine candidate has secured a number of substantial deals with several countries. It is expected to add a final ingredient to its vials enabling them to be kept at regular fridge temperature when the vaccine nears regulatory approval, Reuters reported. Data from late-stage trials should be made available before the end of the year.ĪstraZeneca said late last month that its vaccine candidate had produced a similar immune response in older and younger adults, and adverse responses to the vaccine among the elderly were also found to be lower.Įarlier this month, the British duo said it was keeping its vaccine frozen in large containers. British pharmaceutical giant AstraZeneca is developing its potential Covid-19 vaccine in collaboration with the University of Oxford.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |